Copyright © 2019 EnBiotix, Inc.. All Rights Reserved

Antimicrobial Peptides Platform

Novel, Potent Broad-Spectrum Antimicrobial Peptides

EnBiotix is advancing development of a portfolio of antimicrobial peptides (AMPs) acquired as result of the acquisition of AMP Therapeutics GmbH and a collaboration with Leipzig University.

Extensive preclinical development to date has shown these insect-derived antimicrobial peptides as:

  • Very potent with MICs comparable to small molecules
  • Broad spectrum (Gram- and Gram+ coverage)
  • Showing positive animal model model results
  • Having rapid bacterial cell penetration but no mammalian cell penetration or cytotoxicity/hemolysis

These AMPs have significant potential both as payloads for engineered phage and as stand-alone therapeutics:

  • AMPs for engineered phage payloads and recognition provides plug-and-play potential
  • Addressable indications as stand-alone therapeutics include HAP/VAP, cUTI, cIAI, and ABSSSI

Development of these molecules to date has been funded by a combination of public grants and private financing.